Bioscience Animal Health PCLBKK:BIS +0.98%81 EBITDA Margin % is 5.55% as of Mar. 2026, which is 13% above its 10-year median of 4.89. GuruFocus rates BKK:BIS with a GF Score™ of 81/100 and a GF Value™ of ฿2.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,955 Consumer Packaged Goods companies, Bioscience Animal Health PCL ranks worse than 73.66% on this metric.
Bioscience Animal Health PCL (BKK:BIS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioscience Animal Health PCL EBITDA Margin % Related Terms
Bioscience Animal Health PCL EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioscience Animal Health PCL EBITDA Margin % Chart
For the Packaged Foods subindustry, Bioscience Animal Health PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioscience Animal Health PCL EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioscience Animal Health PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioscience Animal Health PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioscience Animal Health PCL (BKK:BIS) has a EBITDA Margin % of 5.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioscience Animal Health PCL and its competitors. This is 13% above median its historical median of 4.89. Over the past decade, Bioscience Animal Health PCL's EBITDA Margin % has ranged from 3.40 to 6.11. According to the industry distribution chart, Bioscience Animal Health PCL ranks #1440 out of 1955 companies in the Consumer Packaged Goods industry, placing it in the top 73.7%.
Is Bioscience Animal Health PCL's EBITDA Margin % too high?
Bioscience Animal Health PCL's current EBITDA Margin % of 5.55% is 13% above median its 10-year median of 4.89. Over the past 10 years, this metric has ranged from a low of 3.40 to a high of 6.11. The Consumer Packaged Goods industry median EBITDA Margin % is 9.01. Bioscience Animal Health PCL's value of 5.55% is 38.4% below this industry median. Based on the distribution chart, Bioscience Animal Health PCL ranks #1440 out of 1955 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Bioscience Animal Health PCL has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioscience Animal Health PCL's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Bioscience Animal Health PCL ranks #1440 out of 1955 companies for EBITDA Margin %. This places Bioscience Animal Health PCL in the lower half of its industry. The industry median EBITDA Margin % is 9.01. Bioscience Animal Health PCL's value of 5.55% is 38.4% below this benchmark. Historically, Bioscience Animal Health PCL's own EBITDA Margin % has ranged from 3.40 to 6.11 over the past decade. While the company's 10-year median is 4.89 vs. the industry median of 9.01, Bioscience Animal Health PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 9.01, based on 1,955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioscience Animal Health PCL's current EBITDA Margin % of 5.55% is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioscience Animal Health PCL and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 9.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioscience Animal Health PCL's current EBITDA Margin % is 5.55%, which is 13% above median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioscience Animal Health PCL stock overvalued right now?
Based on GuruFocus' analysis, Bioscience Animal Health PCL (BKK:BIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.87, compared to a current price of ฿2.06 — trading 28.2% below its estimated fair value. The current EBITDA Margin % is 5.55%, which is 13% above median its 10-year median of 4.89 and 38.4% below the Consumer Packaged Goods industry median of 9.01. Bioscience Animal Health PCL's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioscience Animal Health PCL (BKK:BIS), the current EBITDA Margin % is 5.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioscience Animal Health PCL (BKK:BIS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioscience Animal Health PCL stock appears to be undervalued.
The current stock price of ฿2.06 is trading 28.2% below its estimated GF Value™ of ฿2.87.
GuruFocus considers Bioscience Animal Health PCL to be Modestly Undervalued.
Key valuation signals for BKK:BIS:
EBITDA Margin %: 5.55% (13% above median its 10-year median of 4.89)
GF Value™: ฿2.87 vs. price of ฿2.06 (28.2% below fair value)
Industry Position: 38.4% below the Consumer Packaged Goods median (#1440 of 1955)
No single metric tells the full story. See the BKK:BIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioscience Animal Health PCL along with its subsidiaries is engaged in the manufacturing, import and distribution of pharmaceutical supplies, medical devices, equipment and products for livestock and companion animals (pets). Geographically, the company generates revenue from Thailand, and also has presence in other countries.
81GF Score
Get the complete analysis for BKK:BIS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIS has been successfully added to your 
